UBS Group
CADL icon

UBS Group’s Candel Therapeutics CADL Stock Holding History

UBS Group’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$734K Buy
149,855
+45,516
+44% +$248K ﹤0.01% 5783
2025
Q4 		$590K Buy
104,339
+10,268
+11% +$55.2K ﹤0.01% 5974
2025
Q3 		$480K Buy
94,071
+11,904
+14% +$68.8K ﹤0.01% 6122
2025
Q2 		$416K Sell
82,167
-104,927
-56% -$540K ﹤0.01% 6161
2025
Q1 		$1.06M Buy
187,094
+30,288
+19% +$247K ﹤0.01% 5248
2024
Q4 		$1.36M Buy
156,806
+147,360
+1,560% +$871K ﹤0.01% 5075
2024
Q3 		$65.5K Buy
9,446
+3,441
+57% +$21.4K ﹤0.01% 6650
2024
Q2 		$37.2K Buy
6,005
+5,995
+59,950% +$45K ﹤0.01% 6911
2024
Q1 		$16 Sell
10
-11,911
-100% -$17.7K ﹤0.01% 9056
2023
Q4 		$17.5K Buy
11,921
+11,911
+119,110% +$11.6K ﹤0.01% 7183
2023
Q3 		$9 Hold
10
– – ﹤0.01% 9226
2023
Q2 		$13 Hold
10
– – ﹤0.01% 8717
2023
Q1 		$14 Sell
10
-785
-99% -$1.53K ﹤0.01% 9444
2022
Q4 		$1.42K Sell
795
-3,386
-81% -$6.7K ﹤0.01% 9874
2022
Q3 		$13K Buy
4,181
+374
+10% +$1.27K ﹤0.01% 8009
2022
Q2 		$12K Buy
3,807
+1,807
+90% +$7.24K ﹤0.01% 7637
2022
Q1 		$10K Sell
2,000
-2,447
-55% -$12.2K ﹤0.01% 8397
2021
Q4 		$34K Buy
4,447
+1,447
+48% +$14K ﹤0.01% 7255
2021
Q3 		$33K Buy
+3,000
New +$24.9K ﹤0.01% 6662

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's CADL Position: Q1 2026 in Review

UBS Group increased its Candel Therapeutics (CADL) stake by 44% in Q1 2026, buying an estimated $248K and bringing the position to 149,855 shares worth $734K. The position accounts for ﹤0.01% of the portfolio, ranked #5783.

UBS Group first reported a position in CADL in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.36M in Q4 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • UBS Group held 149,855 shares of Candel Therapeutics worth $734K as of Q1 2026.
  • UBS Group bought 45,516 Candel Therapeutics shares in Q1 2026, an estimated $248K.
  • Candel Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5783 holding.
  • UBS Group first reported a position in Candel Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • UBS Group's Candel Therapeutics position peaked at $1.36M in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.